Internet Archive Scholar

Photobiomodulation Therapy Prevents Dysgeusia Chemotherapy-Induced in Breast Cancer Women Treated with Doxorubicin Plus Cyclophosphamide: A Triple-Blinded, Randomized, Placebo-Controlled Clinical Trial [post]

Malta Cássia Emanuella Nóbrega, Anna Clara Aragão Matos Carlos, Manuele Carine Maciel de Alencar, Eveline Fernandes Alves e Silva, Victor Bruno Caitano Nogueira, Ana Paula Negreiros Nunes Alves, Fábio Figueiredo Chaves, José Fernando Bastos de Moura, Paulo Goberlânio Barros Silva
2021 unpublished

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (890.8 kB)
https://web.archive.org/web/20210824212137/https://assets.researchsquare.com/files/rs-687053/v1/bee1119e-8695-41c4-9328-9cded1372984.pdf?c=1629470356

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Purpose To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC). Methods This is a phase II, randomized, triple-blind, placebo-controlled clinical trial involving 112 breast cancer patients treated with AC. The patients were divided equally into two groups: a test group treated with 2 J red laser and 3 J infrared laser on 21 points that were symmetrically distributed on the tongue on day 0 of
more » ... cycles of AC, and an equal placebo group treated with simulated PBMT to blind the patient, evaluator, and statistician. The clinicopathological and sociodemographic data, results of the hematological tests, taste test, and subjective taste analysis, and the QoL, ECOG performance status, body mass index, and other side effects were recorded. The data were analyzed using ANOVA-RM/Bonferroni, Friedman/Dunn, and chi-square/Fisher's exact tests. Results PBMT patients showed less objective and subjective taste loss (p < 0.05). On the other hand, the placebo group showed a higher ECOG status (p = 0.037) and more significant weight loss (p < 0.001) after four cycles of AC. The QoL was significantly higherin the PBMT group (p < 0.05) at all assessment periods, and PBMT treatment also reduced the incidence of cachexia (p = 0.020), anorexia (p < 0.001), diarrhea (p = 0.040), oral mucositis (p = 0.020), and vomiting (p = 0.008). Conclusion PBMT reduced the taste loss and improved the overall health status and QoL of patients with breast cancer treated with AC. Trial registration : Brazilian Clinical Trials Registry (www.ensaiosclinicos.gov.br) approval numberRBR-9qnm34y, registered on 01/05/2021
doi:10.21203/rs.3.rs-687053/v1 fatcat:gro2dmmfkjgmdggwdzap6w4tu4
Open Access
Citation

Malta Cássia Emanuella Nóbrega, Anna Clara Aragão Matos Carlos, Manuele Carine Maciel de Alencar, Eveline Fernandes Alves e Silva, Victor Bruno Caitano Nogueira, Ana Paula Negreiros Nunes Alves, Fábio Figueiredo Chaves, José Fernando Bastos de Moura, Paulo Goberlânio Barros Silva. "Photobiomodulation Therapy Prevents Dysgeusia Chemotherapy-Induced in Breast Cancer Women Treated with Doxorubicin Plus Cyclophosphamide: A Triple-Blinded, Randomized, Placebo-Controlled Clinical Trial." (2021)